CEACAM5
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a cell surface glycoprotein that is a member of the carcinoembryonic antigen family, which contains 12 glycoproteins. It is used as a clinical biomarker for many different cancers. It may promote tumor development, metastasis, and cell adhesion by inhibiting differentiation and apoptosis, while disrupting tissue architecture through its role as a cell adhesion molecule.1,2
Understanding the Role of CEACAM5
This animation explains the role of the CEACAM5 glycoprotein in the inhibition of cell differentiation and apoptosis, which can promote tumor growth and metastasis.
Expression in Cancer
Anti-CEACAM5 Antibodies
Therapies targeting CEACAM5 are currently in development for the treatment of multiple cancer types. This table outlines therapies in the pipeline.
|
Anti-CEACAM5 Antibodies in the Pipeline |
|
|
Generic Drug Name |
Potential Indications |
|
Tusamitamab ravtansine1-3 |
An antibody-drug conjugate targeting CEACAM5 being evaluated for the treatment of patients with non-small cell lung cancer, metastatic breast cancer, and metastatic pancreatic adenocarcinoma. |
